Eli Lilly announced acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company targeting vaccines for shingles, staph infections, and Epstein-Barr virus. The company also hired former FDA vaccine regulator Dr. Peter Marks. Reported total deal values differ between sources at up to $3.8 billion or nearly $4 billion.
No left-leaning sources covered this
“Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know”
Read at CNBC →No right-leaning sources covered this
Acquisitions signal corporate control of vaccine pipelines for shingles, staph, and EBV while the Marks hiring illustrates revolving-door concerns and risks of prioritizing shareholder returns over access.
“Industry consolidation and need for public oversight”
Moves reflect standard strategy shaped by federal incentives and liability shields, with the Marks hiring underscoring regulatory capture between agency and industry.
“Institutional skepticism and distorted market incentives”
Transactions represent voluntary capital allocation toward new candidates, though the Marks hiring shows firms navigating regulatory barriers rather than pure product competition.
“Voluntary exchange versus state-shaped incentives”
All views over-accept the capture narrative around Marks and treat the deals as a coherent vaccine push despite early-stage risks, prior failures, and Lilly's non-vaccine revenue base.
“Unexamined assumptions on deal rationale and regulatory strategy”
Ratings by MBFC